Navigation Links
NeurogesX to Present at UBS Global Life Sciences Conference
Date:9/17/2009

ment activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Sara Pellegrino (investors)
    (646) 536-7002
    spellegrino@theruthgroup.com

    Jason Rando (media)
    (646) 536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at Upcoming Fall Conferences
2. NeurogesX Appoints New Board Director and Audit Committee Chairman
3. NeurogesX Reports Second Quarter 2009 Results
4. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
5. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
6. NeurogesX Added to Russell 3000 Index
7. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
8. NeurogesX to Present at Needham Life Sciences Conference
9. NeurogesX Receives European Commission Approval for Qutenza(TM)
10. NeurogesX Reports First Quarter 2009 Results
11. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Cambridge Semantics ... driven by Semantic Web technology, and Informa ... and services for the academic and scientific, professional ... joint solution ‘Smart Data Lake for Clinical Trial ... the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... Miami, FL (PRWEB) April 16, 2015 ... therapy cap distribution and physician network in Europe ... marketing company has appointed Fernando Bermúdez, former Business ... Director. , An industry veteran, Mr. Bermúdez’s professional ... by 75% in Spain, while also penetrating the ...
(Date:4/16/2015)... 2015  Schulman Associates IRB, Inc., the industry-leading central ... long-term lease on Laboratory Drive in the heart of ... The location will house review board and service staff, ... reviews and customer service to clients. ... in the deal, while Capital Associates Management, LLC represented ...
(Date:4/16/2015)... 16, 2015 According to the ... an outside source was ranked first among the ... related to lifting, pushing, pulling, holding, carrying, or ... costs. The David Round Company takes statistics like ... working hard to develop and design equipment that ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Schulman IRB to Open Office in Research Triangle Park, N.C. 2The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... European research initiative EUREKA will be represented with its ... of HANNOVER MESSE 2010 (19-23 April). This presentation underlines ... and Development in Hall 2. "We want ... central European platform with respect to the international networking ...
... Md. , and INDIANAPOLIS , Feb. 10 ... Corporation (Nasdaq: UTHR ), announced today that it has ... development of ImmuneWorks, lead compound, IW001, a purified bovine Type ... Fibrosis (IPF) and Primary Graft Dysfunction (PGD) in patients receiving ...
... PLANTATION, Fla. and DALLAS , ... full service Contract Biomanufacturing Company and Macrocyclics, Inc., ... today their collaborative agreement on Chelation and Bioconjugation. ... Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing. ...
Cached Biology Technology:European research initiative EUREKA presented at Research & Technology for the first time 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration 2
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... SAN ANTONIO (Jan. 7, 2011) Resveratrol, a compound ... a study published this week, researchers at the UT ... in which resveratrol exerts these beneficial health effects. ... from cells that manufacture and store fat, the team ...
... January 7, 2011 By rethinking what happens on ... discovered that Bacillus subtilis biofilm colonies exhibit ... liquidsand even vapors. Centimeters across yet only hundreds ... the surfaces of everything from pipes to teeth and ...
... Indiana University-Purdue University Indianapolis has received $943,000 from ... and diversity of future life science researchers. ... Research Mentoring in the Biological Sciences (URM) Program, ... URM is designed to broaden participation of African ...
Cached Biology News:Grape ingredient resveratrol increases beneficial fat hormone 2A pesky bacterial slime reveals its survival secrets 2A pesky bacterial slime reveals its survival secrets 3Increasing diversity of future life science researchers 2